Picture of Accelerate Diagnostics logo

AXDX Accelerate Diagnostics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-15.6%
3m-79.14%
6m-85.38%
1yr-84.67%
Volume Change (%)
10d/3m-40.25%
Price vs... (%)
52w High-91.68%
50d MA-23.72%
200d MA-79.76%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-4584.59%
Return on Equityn/a
Operating Margin-587.4%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Accelerate Diagnostics EPS forecast chart

Profile Summary

Accelerate Diagnostics, Inc. is an in-vitro diagnostics company. The Company is engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. Its in-vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
December 24th, 2012
Public Since
October 27th, 1993
No. of Shareholders
124
No. of Employees
179
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
20,085,267

AXDX Share Price Performance

Upcoming Events for AXDX

Q4 2023 Accelerate Diagnostics Inc Earnings Release

Q4 2023 Accelerate Diagnostics Inc Earnings Call

Q1 2024 Accelerate Diagnostics Inc Earnings Release

Accelerate Diagnostics Inc Annual Shareholders Meeting

Q2 2024 Accelerate Diagnostics Inc Earnings Release

Similar to AXDX

Picture of Acutus Medical logo

Acutus Medical

us flag iconNASDAQ Capital Market

Picture of Adapthealth logo

Adapthealth

us flag iconNASDAQ Capital Market

Picture of Aethlon Medical logo

Aethlon Medical

us flag iconNASDAQ Capital Market

Picture of Agape ATP logo

Agape ATP

us flag iconNASDAQ Capital Market

Picture of Agendia NV logo

Agendia NV

us flag iconNASDAQ Capital Market

FAQ